Environment &
Food & Beverage
Cosmetics
Life Sciences
Metal & Mining Industry
Petrochemical & General Chemistry
Automotive Related & Interior Materials
InertSearch (Application Library)
Index
Application
LC
Document No. Index
LB401 - 500 of Application List
| No. | Description | Column |
|---|---|---|
| LB401 | Analysis of Preservatives and Sweetener (InertSustain AQ-C18) | InertSustain AQ-C18 |
| LB402 | Analysis of Preservatives and Sweetener (InertSustain AQ-C18) | InertSustain AQ-C18 |
| LB403 | Analysis of Preservatives and Sweetener (Inertsil ODS-4) | Inertsil ODS-4 |
| LB404 | Analysis of Preservatives and Sweetener (Inertsil ODS-SP) | Inertsil ODS-SP |
| LB405 | Analysis of Phenolic antioxidants | InertSustainSwift C18 |
| LB406 | Analysis of Hippuric acid | InertSustain AQ-C18 HP |
| LB407 | Analysis of Fluconazole (Under the Condition of the Japanese Pharmacopoeia, Fluconazole Capsules) | Inertsil WP300 C18 |
| LB408 | Analysis of Fluconazole (Under the Condition of the Japanese Pharmacopoeia) | InertSustainSwift C18 |
| LB409 | Analysis of Mesalazine (Under the Condition of the draft for the Japanese Pharmacopoeia, Mesalazine Extended-release Tablets) | Inertsil ODS-4 |
| LB410 | Analysis of Medroxyprogesterone acetate (Under the Condition of the draft for the Japanese Pharmacopoeia) | Inertsil WP300 C18 |
| LB411 | Analysis of Medroxyprogesterone acetate (Under the Condition of the draft for the Japanese Pharmacopoeia) | Inertsil WP300 C18 |
| LB412 | Analysis of Eplerenone (Under the Condition of the draft for the Japanese Pharmacopoeia) | InertSustainSwift C18 |
| LB413 | Analysis of Eplerenone (Under the Condition of the draft for the Japanese Pharmacopoeia) | InertSustainSwift C18 |
| LB414 | Analysis of Esomeprazole magnesium (Under the Condition of USP 38-NF33, Esomeprazole magnesium Extended-release Tablets) | InertSustain C18 |
| LB415 | Analysis of Methotrexate (Under the Condition of the draft for the Japanese Pharmacopoeia, Methotrexate Tablets) | Inertsil ODS-4 |
| LB416 | Analysis of Vitamin K (InertSustain AQ-C18) | InertSustain AQ-C18 |
| LB417 | Analysis of Vitamin K (InertSustainSwift C18) | InertSustainSwift C18 |
| LB418 | Analysis of Vitamin K (Inertsil WP300 C18) | Inertsil WP300 C18 |
| LB419 | Analysis of Acetaminophen (Under the Condition of the Japanese Pharmacopoeia) （InertSustain C18） | InertSustain C18 |
| LB420 | Analysis of Acetaminophen (Under the Condition of the Japanese Pharmacopoeia) （InertSustainSwift C18） | InertSustainSwift C18 |
| LB421 | Analysis of Nonsteroidal anti-inflammatory drug （InertSustain Phenylhexyl） | InertSustain Phenylhexyl |
| LB422 | Analysis of Nonsteroidal anti-inflammatory drug （InertSustain C18） | InertSustain C18 |
| LB423 | Analysis of Nonsteroidal anti-inflammatory drug （InertSustain Phenyl） | InertSustain Phenyl |
| LB424 | Analysis of Eplerenone(Under the Condition of the Japanese Pharmacopoeia 17th edition, Eplerenone Tablets) | Inertsil ODS-3 |
| LB425 | Analysis of Diflorason Diacetate(Under the Condition of the Japanese Pharmacopoeia 17th edition) | InertSustain C18 |
| LB426 | Analysis of Diflorason Diacetate(Under the Condition of the Japanese Pharmacopoeia 17th edition) | InertSustain C18 |
| LB427 | Analysis of Zonisamide | InertSustain AQ-C18 |
| LB428 | Analysis of Zonisamide | InertSustain AQ-C18 |
| LB429 | Analysis of Tulobuterol(Under the Condition of the Japanese Pharmacopoeia 17th edition) | InertSustain C18 |
| LB430 | Analysis of Tulobuterol Hydrochloride(Under the Condition of the Japanese Pharmacopoeia 17th edition) | InertSustain C18 |
| LB431 | Analysis of Haloperidol(Under the Condition of the Japanese Pharmacopoeia 17th edition) | Inertsil ODS-4 |
| LB432 | Analysis of Haloperidol(Under the Condition of the Japanese Pharmacopoeia 17th edition, Haloperidol Tablets) | Inertsil ODS-4 |
| LB433 | Analysis of Povidone(Under the Condition of the Japanese Pharmacopoeia 17th edition, (4) 1-Vinyl-2-pyrrolidone) | InertSustain AQ-C18 |
| LB435 | Analysis of Povidone(Under the Condition of the Japanese Pharmacopoeia 17th edition, (6) 2-Pyrrolidone) | InertSustain AQ-C18 |
| LB436 | Analysis of Mesalazine(Under the Condition of the Japanese Pharmacopoeia, (7) Aniline) | InertSustain C18 |
| LB437 | Analysis of BSA Digests (InertSustain AQ-C18) | InertSustain AQ-C18 |
| LB438 | Analysis of BSA Digests (InertSustainSwift C18) | InertSustainSwift C18 |
| LB439 | Analysis of Myoglobin Digests (InertSustain AQ-C18) | InertSustain AQ-C18 |
| LB440 | Analysis of Myoglobin Digests (InertSustainSwift C18) | InertSustainSwift C18 |
| LB441 | Analysis of Aflatoxin M1(InertSustain AQ-C18) | InertSustain AQ-C18 |
| LB442 | Analysis of Aflatoxin M1(Inertsil ODS-3) | Inertsil ODS-3 |
| LB443 | Analysis of Nucleotide | InertSustain AQ-C18 |
| LB444 | Analysis of Pazufloxacin mesilate(Under the Condition of the draft for the Japanese Pharmacopoeia) | Inertsil ODS-2 |
| LB445 | Analysis of Pazufloxacin mesilate (Under the Condition of the Japanese Pharmacopoeia 18th edition) | Inertsil ODS-3 |
| LB446 | Analysis of Hydrocortisone butyrate(Under the Condition of the draft for the Japanese Pharmacopoeia) | Inertsil ODS-3 HP |
| LB447 | Analysis of Mesalazine(Under the Condition of the draft for the Japanese Pharmacopoeia, (6) 2-Aminophenol and 4-Aminophenol) | InertSustainSwift C18 HP |
| LB448 | Analysis of Mesalazine(Under the Condition of the draft for the Japanese Pharmacopoeia, (8) 3-Aminophenol, 3-Aminobenzoic acid, Gentisic acid, Salicylic acid, other related substances and total related substance) | InertSustain C8 |
| LB449 | Analysis of Lansoprazole(Under the Condition of the Japanese Pharmacopoeia) | InertSustain C18 |
| LB450 | Analysis of Tranexamic acid(Under the Condition of the Japanese Pharmacopoeia) | InertSustain AQ-C18 |
| LB451 | Analysis of Tranexamic acid(Under the Condition of the Japanese Pharmacopoeia) | InertSustain AQ-C18 |
| LB452 | Analysis of Tranexamic acid(Under the Condition of the Japanese Pharmacopoeia, Tranexamic acid Tablets) | InertSustain AQ-C18 |
| LB453 | Analysis of Tranexamic acid(Under the Condition of the Japanese Pharmacopoeia, Tranexamic acid Capsules) | Inertsil ODS-4 |
| LB455 | Analysis of Polar Peptides | InertSustain AQ-C18 |
| LB456 | Analysis of Benzenediols | InertSustain C18 |
| LB457 | Analysis of Hydroxynaphthoquinones | InertSustain C18 |
| LB458 | Analysis of Glyburide (Under the Condition of USP 39-NF34) | Inertsil C8 |
| LB459 | Analysis of Acetaminophen (Under the Condition of USP 39-NF34, Acetaminophen Capsules) | Inertsil ODS-3 |
| LB460 | Analysis of Estradiol (Under the Condition of USP 39-NF34) | Inertsil ODS-3 |
| LB461 | Analysis of Phenylephrine Hydrochloride (Under the Condition of USP 39-NF34, Phenylephrine Hydrochloride Injection) | InertSustain C18 |
| LB462 | Analysis of Cephalexin (Under the Condition of USP 39-NF34) | InertSustain C18 |
| LB463 | Analysis of Ibuprofen (Under the Condition of USP 39-NF34, Ibuprofen Oral Suspension) | InertSustain C8 |
| LB464 | Analysis of Ultraviolet absorbers | InertSustain C18 |
| LB465 | Analysis of Fungicides | InertSustain C18 |
| LB466 | Analysis of Oxalic acid | InertSustain Amide |
| LB467 | Analysis of Vitamin D | Inertsil ODS-HL |
| LB468 | Analysis of Vitamin K（InertSustainSwift C8） | InertSustainSwift C8 |
| LB469 | Analysis of Vitamin K（Inertsil ODS-HL） | Inertsil ODS-HL |
| LB470 | Simultaneous analysis of Amino acids derivatized with 4-fluoro-7-nitro-2,1,3-benzoxadiazole (NBD-F) | InertSustainSwift C18 |
| LB471 | Analysis of Tramadol Hydrochloride (Under the Condition of the draft for the Japanese Pharmacopoeia) | InertSustain C8 |
| LB472 | Analysis of Tramadol Hydrochloride (Under the Condition of the draft for the Japanese Pharmacopoeia) | InertSustainSwift C8 |
| LB473 | Analysis of Solifenacin Succinate (Under the Condition of the draft for USP) | InertSustain Phenyl |
| LB474 | Analysis of Solifenacin Succinate (Under the Condition of the draft for USP) | InertSustain Phenylhexyl |
| LB475 | Analysis of Solifenacin Succinate (Under the Condition of the draft for USP) | Inertsil Ph-3 |
| LB476 | Analysis of Solifenacin Succinate (Under the Condition of the draft for USP) | Inertsil Ph |
| LB477 | Analysis of Povidone(Under the Condition of the Japanese Pharmacopoeia 17th edition, (7) Formic acid) | InertSphere FA-1 |
| LB479 | Analysis of Lactosucrose | InertSustain Amide |
| LB480 | Analysis of 13 kinds of Aldehydes (Directed by Pre-Column Method with DNPH) | InertSustain C18 |
| LB481 | Analysis of Bromate ion in tap water | SYPRON AX-1 |
| LB482 | Analysis of Glycyrrhiza (Under the Condition of the Japanese Pharmacopoeia 17th edition) | Inertsil ODS-4 |
| LB483 | Analysis of Minocycline Hydrochloride (Under the Condition of the Japanese Pharmacopoeia 17th edition) | InertSustainSwift C8 |
| LB484 | Analysis of Catecholamine metabolite | InertSustainSwift C18 |
| LB485 | Analysis of Pyridoxal Phosphate Hydrate (Under the Condition of the Japanese Pharmacopoeia, (4) Related subatances) | InertSustain AQ-C18 |
| LB486 | Analysis of Clomipramine Hydorochloride (Under the Condition of the Japanese Pharmacopoeia, Clomipramine Hydorochloride Tablets) | Inertsil ODS-3 |
| LB487 | Analysis of Verapamil Hydrochloride (Under the Condition of the Japanese Pharmacopoeia, Verapamil Hydrochloride Tablets) | InertSustain C18 |
| LB488 | Analysis of Sucralose | InertSustain C18 |
| LB489 | Analysis of Azosemide (Under the Condition of the draft for the Japanese Pharmacopoeia, Azosemide Tablets) | InertSustain C18 |
| LB490 | Analysis of Nucleosides | InertSustain Amide |
| LB491 | Analysis of Nucleobases | InertSustain Amide |
| LB493 | Analysis of Tryptophan metabolites | InertSustain Amide |
| LB494 | Analysis of Corticosteroids | Inertsil ODS-HL |
| LB495 | Analysis of Tyramine and Histamine | InertSustain Amide |
| LB496 | Analysis of Tetrodotoxin | InertSustain Amide |
| LB497 | Analysis of Amino acids | InertSustain Amide |
| LB498 | Analysis of Analysis of Tasty Components | InertSustain Amide |
| LB499 | Analysis of Purine bases | InertSustain Amide |
| LB500 | Analysis of Melamine related compounds | InertSustain Amide |